205807-59-6Relevant articles and documents
Process development of a dual MMP/TNF inhibitor (SDZ 242-484)
Koch, Guido,Kottirsch, Georg,Wietfeld, Bernhard,Kuesters, Ernst
, p. 652 - 659 (2013/09/06)
The compound (2R,3S)-N-4-((S)-2,2-Dimethyl-1-methylcarbamoyl-propyl)-N-1-hydroxy-2- hydroxymethyl-3-(4-methoxy-phenyl)-succinamide (1; SDZ 242-484) shows antiinflammatory effects due to inhibition of matrix metalloproteases (MMP) and tumor necrosis factor
β-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme
Kottirsch, Georg,Koch, Guido,Feifel, Roland,Neumann, Ulf
, p. 2289 - 2293 (2007/10/03)
Novel hydroxamate inhibitors of tumor necrosis factor converting enzyme (TACE) and matrix metalloproteases (MMPs) have been synthesized via the Claisen-Ireland rearrangement. Aryl residues have been introduced to fill the enzyme's P1′ specificity pocket. The best compound inhibits MMPs and TACE with nanomolar potency and inhibits the release of TNFα from cells with an IC50 of 48 nM. Oral administration to rats inhibits the LPS-induced plasma TNFα levels with an ED50 of 1 mg/kg.